Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Foslevodopa/Foscarbidopa at Different Infusion Sites in PD
NCT05094050Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Jan 2022
- Primary completion
- Mar 2023
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of foslevodopa and foscarbidopa in Parkinson's disease (PD) (4 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum Observed Plasma Concentration (Cmax) of Levodopa up to 8 days, Area Under the Plasma Concentration-Time Curve (AUC) for the 24-hour Interval of Levodopa up to 8 days and 1 more. Started Jan 2022; status: completed.
02
Drugs
foslevodopafoscarbidopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05094050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05094050.